In Vitro Testing of Drugs that Affect
Tumor Cells
using CellaGlo™-Tox HT
THIS PAGE IS BEING UPDATED. PLEASE RETURN SOON.
This page is presently being updated with new information. We apologize for the inconvenience.
Please contact HemoGenix® for more information at contractresearch@hemogenix.com or call (719) 264-6250.
Types of Toxicity Studies Available
The majority of studies performed by HemoGenix® incorporate a Complete Service, Full Report that can be used for an IND application. More recently, Sponsors have requested a more streamlined study and studies involving high-throughput screening. For this reason, HemoGenix® now provides 3 types of study format.
- Complete Service, Full Report Study: Fully customized study that includes the Study Plan, Draft Text and Final Text Report with QA audit.
- Rapid Toxicity Study: A customized study that includes the Study Plan and full protocol, raw results and graphical data in a single Excel Workbook. No formal text report and no QA audit is performed. This type of study is designed for early drug development. No interpretation or conclusions are provided.
- High-Throughput Screening Study (presently only available for human studies): A screening study is designed for high-throughput screening of compounds during ADME/Tox screening in multiples of 5 on specific cell populations to provide the most important ranking information. The full protocol, raw results and graphical data are provided in an Excel Workbook. No interpretation or conclusions are provided. This type of Screening Study is part of the ComparaTOX™ HT Platform.